The present disclosure provides a soluble P-selectin (sP-sel) interfering the interaction between stem cells and niches to mobilize stem cells from bone marrow. The mobilization of stem cells with sP-sel can treat a subject in need of preservation, repair, or regeneration of a tissue, or revascularization.

The present invention relates to the lectin protein for the treatment and prevention of neurodegenerative diseases. The invention further relates to the recombinant lectin protein is derived from Sclerotium rolfsii lectin having sequence 60% homologous to SEQ ID NO: 4 for the treatment and prevention of Neurodegenerative diseases. The invention specifically relates to lectin protein and its variants is derived from Sclerotium rolfsii lectin having sequence 60% homologous to SEQ ID NO: 4 for the treatment of prevention of Parkinson's disease, Alzheimer's disease, Dementia and symptoms of dementia.

The present invention relates to a method for increasing embryo implantation rate in mother's uterus in mammals by administering to the uterus of a mammal an effective amount of beta-galactoside-binding lectin or derivatives thereof, as well as to a product comprising said lectin.

Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.

The disclosure relates to uses of a purified or isolated lectin to kill bacteria, viruses, and other pathogens. In certain embodiments, the disclosure relates to method of treating or preventing an infection comprising administering a purified or isolated galectin to a subject in need thereof. In certain embodiments, the subject is at risk of, exhibiting symptoms of, or diagnosed with a pathogenic infection.

The disclosure relates to uses of a purified or isolated lectin to kill bacteria, viruses, and other pathogens. In certain embodiments, the disclosure relates to method of treating or preventing an infection comprising administering a purified or isolated galectin to a subject in need thereof. In certain embodiments, the subject is at risk of, exhibiting symptoms of, or diagnosed with a pathogenic infection.

The present invention relates to a lectin for use in the treatment, reduction in progression and curing of inflammation in a subject in need thereof. Pharmaceutical compositions comprising said lectin are also described. The lectin may comprise an amino acid sequence having sequence of SEQ ID NO: 1 or at least 60% homology to SEQ ID NO: 2.

A method of diagnosing long-COVID in a subject, the method comprising: (a) measuring the level of one or more biomarkers in a test sample obtained from the subject, and (b) comparing the level of the one or more biomarkers in the test sample with a healthy control and/or an acute COVID-19 reference level value of said one or more biomarkers, wherein an increase in the level of the one or more biomarkers in the test sample relative to the healthy control and/or acute COVID-19 reference level value of said one or more biomarkers is indicative of long-COVID diagnosis, and wherein the one or more biomarkers are selected from Table 5. In one embodiment, the one or more biomarkers include ANG-1, P-Sel and MMP-1. A method of treating long-COVID comprising administering to a subject one or more of the biomarkers are selected from Table 5.

Provided herein are methods of inducing immune tolerance to graft cells in a human patient in need thereof comprising administering to the patient (i) the graft cells. (ii) a chimeric FasL protein conjugated to a hydrogel, and (iii) transient sirolimus.

Provided herein are methods of inducing immune tolerance to graft cells in a human patient in need thereof comprising administering to the patient (i) the graft cells. (ii) a chimeric FasL protein conjugated to a hydrogel, and (iii) transient sirolimus.